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Abstract
Thirty-year-old observations report frequent asymptomatic Clos-
tridium difﬁcile carriage among cystic ﬁbrosis (CF) patients. In this
case-control study, we found more carriers among CF patients
than controls (47% versus 11%), but most strains carried by CF
patients were non-toxigenic (77% versus 17%). Among CF
patients, carriers were younger, with more severe pulmonary
disease than non-carriers. Strains belonged to multiple PCR-rib-
otypes, suggesting that these CF patients did not acquire strains
from each other.
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Introduction
Clostridium difﬁcile infection (CDI) is an important cause of
diarrhoea and colitis. The most important risk factors are
exposure to healthcare institutions and the use of antibiotics.
Other associated factors are advanced age, severe co-mor-
bidity, decreased humoral immunity against C. difﬁcile toxins
and the use of proton pump inhibitors. Intestinal colonization
with C. difﬁcile may lead to disease, but also to asymptomatic
carriage. The role of asymptomatic carriers in the spread of
CDI is unclear as yet [1], as is the reason why some become
carriers and others develop disease.
Several studies have suggested that patients with cystic
ﬁbrosis (CF) are often asymptomatic carriers of C. difﬁcile [2–
4], which is not surprising given their frequent use of
antibiotics and exposure to hospitals. However, these obser-
vations were made in the 1980s, when the incidence of CDI
was lower than now and epidemic strains such as PCR
TABLE 1. Characteristics of Clostridium difﬁcile carriers and
non-carriers among controls
Continuous
variables
Carriage No carriage
pN Median IQR N Median IQR
Age (years) 12 76 69–83 96 70 56–82 0.257
Total deﬁned daily
doses of antibiotics
consumed in the
previous 3 months
7 0 0–7 81 0 0–4 0.648
Charlson co-
morbidity index
12 3 0–4 96 2 0–3 0.531
Duration of current
admission (days)
12 5 3–7 95 4 2–6 0.186
Categorical variables N % N % OR 95% CI
Male sex 12 42 96 48 0.78 0.23–2.62
Use of antibiotics in the previous
3 months
12 67 96 44 2.57 0.73–9.12
Use of ceftazidime in the previous
3 months
12 8 96 1 8.64 0.51-148
Use of ciproﬂoxacine in the
previous 3 months
12 33 93 15 2.82 0.75–11
Use of any immunosuppressant in
the previous 3 months
12 17 95 19 0.86 0.17–4.25
Use of proton pump inhibitor in
the previous 3 months
12 50 96 58 0.71 0.22–2.37
Hospital admission in the previous
3 months
12 33 96 20 2.03 0.55–7.44
Co-morbidity as deﬁned by Charlson index
History of myocardial infarction 12 25 96 15 1.95 0.47–8.11
Congestive heart failure 12 42 96 14 4.56 1.26–17
Peripheral vascular disease 12 8 96 5 1.66 0.18–15
Cerebrovascular disease 12 8 96 9 0.88 0.10–7.61
Dementia 12 0 96 2
Chronic pulmonary disease 12 25 96 15 1.95 0.47–8.11
Rheumatological disease 12 0 96 3
Peptic ulcer disease 12 0 96 4
Diabetes mellitus without
microvascular disease
12 17 95 22 0.71 0.14–3.47
Diabetes mellitus with
microvascular disease
12 8 96 4 2.09 0.21–20
Hemiplegia or paraplegia 12 0 95 1
Renal disease 12 8 96 10 0.78 0.09–6.71
Non-haematological malignancy 12 0 96 24
Leukaemia 12 8 96 0
Lymphoma 12 8 96 2 4.27 0.36–51
Liver cirrhosis with portal
hypertension or hepatic coma
12 17 96 0
Metastasized non-haematological
malignancy
12 0 96 13
HIV infection 12 0 96 0
Results printed in bold face have reached statistical signiﬁcance (p <0.05).
N, number of patients for whom information was available; IQR, interquartile
range; OR, odds ratio.
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ribotype 027 had not yet emerged. Furthermore, the strains
CF patients carry have not been characterized with molecular
methods and predictors of C. difﬁcile carriage among CF
patients have not been investigated. Lastly, why CF patients
apparently seldom develop disease remains unclear. Filling in
these knowledge gaps may provide insight into CDI epidemi-
ology and pathogenesis and have implications for infection
prevention. In this case-control study, we sought to conﬁrm
earlier observations of frequent C. difﬁcile carriage in CF
patients, to characterize their C. difﬁcile strains using molecular
methods, to compare the aforementioned risk factors for CDI
in this group with a control group and to identify predictors of
C. difﬁcile carriage in CF patients.
From June 2012 through to November 2012, all adult CF
patients monitored at Erasmus Medical Center, Rotterdam, a
national CF center, were asked to participate in the study. The
only exclusion criterion was failure to give informed consent.
Inpatients submitted a stool sample on the ward, which was
transported to Leiden University Medical Center the same day.
Outpatients sent a stool sample by mail, which usually arrived
the next day. Stool samples were cultured for C. difﬁcile using
selective media and the alcohol shock method [5]. Strains
were characterized by PCR-ribotyping [6] and PCRs for toxin
genes (TcdA, TcdB and binary toxin genes CdtA and CdtB)
[5,7,8]. Patients described their bowel movements in a diary
[9]. Clinical and epidemiological information was collected
from patient charts.
As controls, we asked all patients present on 10 separate
days between 1 March 2011 and 30 September 2011 on the
internal medicine ward of Bronovo Hospital, The Hague, a
general hospital with 815 beds, to participate in the study.
The distributions of continuous variables were compared
using a Mann–Whitney U-test. Pulmonary function test results
were log-normalized for comparison and compared by t-test.
For associations between categorical variables, odds ratios
(ORs) with 95% conﬁdence intervals (95% CI) were calcu-
lated. IBM SPSS Statistics 20.0 software was used for the
calculations.
Fifty-ﬁve CF patients and 108 controls submitted a stool
sample. Twenty-six (47%) CF patients were carriers vs. 12
TABLE 2. Characteristics of Clostridium difﬁcile carriers and non-carriers among cystic ﬁbrosis patients
Continuous variables
Carriage No carriage
pN Median IQR N Median IQR
Age 26 26 21–39 29 35 26–45 0.066
Total deﬁned daily doses of antibiotics consumed in the previous 3 months 22 75 45–90 25 64 0–71 0.116
Forced expiratory ﬂow between 25% and 75% of vital capacity (% of predicted) 23 16 9–52 28 29 12–58 0.227
Residual volume/total lung capacity ratio (% of predicted) 21 115 84–146 28 91 80–114 0.054
Forced expiratory volume in 1 s (% of predicted) 23 54 32–80 29 73 52–89 0.085
Forced expiratory volume in 1 s/vital capacity ratio (% of predicted) 23 65 60–80 29 74 59–93 0.378
Categorical variables N % N % OR 95% CI
Age under 31 26 62 29 53 2.62 0.88–7.78
Age under 31, adjusted for forced expiratory volume in 1 s <65% of predicted 3.98 1.08–14.67
Forced expiratory ﬂow between 25% and 75% of vital capacity <23% of predicted 23 57 28 43 1.73 0.57–5.28
Residual volume/total lung capacity ratio ≥97% of predicted 21 67 28 46 2.31 0.71–7.45
Forced expiratory volume in 1 s <65% of predicted 23 65 29 38 3.07 0.98–9.59
Forced expiratory volume in 1 s <65% of predicted, adjusted for age less than 31 years 4.61 1.25–17.03
Forced expiratory volume in 1 s/vital capacity ratio <69% of predicted 26 54 29 38 1.91 0.65–5.60
Use of antibiotics in the previous 3 months 26 85 29 69 2.48 0.66–9.31
Use of ceftazidime in the previous 3 months 26 19 28 4 6.43 0.70 - 59
Use of azithromycin in the previous 3 months 26 73 29 48 2.91 0.94–9.02
Use of any immunosuppressant in the previous 3 months 23 26 29 14 2.21 0.54–9.01
Use of proton pump inhibitor in the previous 3 months 25 48 29 41 1.31 0.45–3.84
Admitted to hospital at the time of collection of stool sample 26 15 29 7 2.46 0.41–14.67
Hospital admission in the previous 3 months 26 12 29 7 1.76 0.27–11.5
Chronic sinusitis 25 52 28 32 2.29 0.75–6.98
Exocrine pancreatic insufﬁciency 26 85 29 72 2.10 0.55–8.01
Endocrine pancreatic insufﬁciency 26 27 29 28 0.97 0.29—3.18
History of meconium ileus or distal obstructive syndrome 26 12 29 10 1.13 0.21–6.16
Liver cirrhosis 26 8 29 10 0.72 0.11–4.70
Homozygous for DF508 22 50 29 48 1.07 0.35–3.25
Compound heterozygous for DF508 22 41 29 38 1.13 0.37–3.52
One class I and one class II mutation 22 18 24 4 5.11 0.53–50
One class I and one class III mutation 22 5 24 0
One class I and one class V mutation 22 5 24 0
One class I and second unknown mutation 22 0 25 8
Any class 1 mutation 22 27 25 8 4.31 0.77–24
Two class II mutations 22 50 24 63 0.60 0.19–1.94
One class II and one class IV mutation 22 0 24 4
One class II and one class V mutation 22 23 24 25 0.88 0.23–3.44
Two class IV mutations 22 0 24 4
Results printed in bold face have reached statistical signiﬁcance (p <0.05).
N, number of patients for whom information was available; IQR, interquartile range; OR, odds ratio.
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(11%) controls (OR, 7.17; 95% CI, 3.22–16). Only six (23%)
strains from CF patients were toxigenic, compared with 10
(83%) strains from controls. Strains in both groups belonged to
various PCR ribotypes (CF patients, 009, 010 (seven patients),
012 (2), 035, 039 (5), 046, 078, 097, 140, 151, 169, 207,
unknown (3); controls, 018, 026, 043, 054, 076 (2), 081, 140,
142, unknown (2), one strain was not available). In only two
strains, belonging to PCR ribotype 078 and an unknown
ribotype, both from CF patients, were genes for binary toxin
present.
None of 36 carriers had diarrhoea (a mean of three watery
bowel movements during three consecutive days), as opposed
to ﬁve of 115 non-carriers; information was incomplete in 12
patients.
Among controls, the only statistically signiﬁcant association
was heart failure as deﬁned in the Charlson co-morbidity index
[10] (Table 1).
Cystic ﬁbrosis patients had received more antibiotics than
controls. Among CF patients, surprisingly, carriers were
younger than non-carriers (Table 2). Also, carriers had worse
pulmonary function parameters. Carriage was associated with
severe (class I) mutations in the CFTR gene. Continuous
variables were dichotomized using the median of the whole
population as a cut-off. Because of an inverse relationship
between age and pulmonary function, the odds ratios for
pulmonary function parameters were adjusted for age by
logistic regression analysis to correct for confounding. Age
under 31 years and FEV1 under 65% of predicted were
signiﬁcantly associated with carriage.
Strengths of this study were the detailed data, including
daily deﬁned antibiotic doses, pulmonary function tests and
CFTR mutations, and the molecular characterization of
C. difﬁcile strains. A weakness of this study is the small
number of patients. Furthermore, a comparison of CF
patients with any other patient group is necessarily ﬂawed
because of differences in age and co-morbidities. We tried to
compensate for this by detailed documentation of risk factors
for C. difﬁcile carriage.
In the three studies from the 1980s, carriage rate among
CF patients receiving antibiotics ranged from 22% to 50%,
vs. 0% among those not receiving antibiotics [2–4]. Most of
the colonized patients did not have diarrhoea. Our ﬁnding
of a high asymptomatic carriage rate is compatible with
these studies, but only one study found a similarly low
proportion of toxigenic strains. The association between
carriage and more severe pulmonary disease can probably
be explained by higher antibiotic consumption. The associ-
ation with younger age might tentatively be explained by a
higher exposure to (non-toxigenic) strains circulating in the
community.
Colonization with non-toxigenic C. difﬁcile may protect
against colonization with toxigenic strains [11] and may partially
explain why CF patients seldom develop disease. Non-toxigenic
strains might be less efﬁcient at establishing long-term carriage
than toxigenic C. difﬁcile [12,13]. We hypothesize that, due to
differences in colonic mucus or microbiome [14], non-toxigenic
strains can colonize CF patients more efﬁciently than non-CF
patients. Questions remain over how non-toxigenic C. difﬁcile
strains can establish durable colonization in CF patients, and
whether other factors than colonization by non-toxigenic
strains protect CF patients from CDI.
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